Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study.

Jonathan StrosbergNobumasa MizunoToshihiko DoiEnrique GrandeJean-Pierre DelordRonnie Shapira-FrommerEmily BergslandManisha ShahMarwan FakihShunji TakahashiSarina A Piha-PaulBert O'NeilSajeve ThomasMartijn P LolkemaMenghui ChenNageatte IbrahimKevin NorwoodJulien Hadoux

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Pembrolizumab monotherapy showed limited antitumor activity and manageable safety in patients with previously treated advanced well-differentiated NETs.

Keyphrases

phase ii
open label
neuroendocrine tumors
clinical trial
advanced non small cell lung cancer
phase iii
placebo controlled
double blind
randomized controlled trial
newly diagnosed
combination therapy
study protocol